Drug Profile


Alternative Names: BL 8020; Ribavirin/hydroxychloroquine

Latest Information Update: 15 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genoscience
  • Developer BioLineRx
  • Class Antimalarials; Antivirals; Quinolines; Ribonucleosides; Small molecules
  • Mechanism of Action Autophagy inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatitis C

Most Recent Events

  • 15 Feb 2016 Phase-I/II development is ongoing in France (PO)
  • 17 Mar 2014 BioLineRx enters into a global collaboration agreement covering the transfer of development rights to Genoscience and Panmed
  • 24 Apr 2013 Phase-I/II clinical trials in Hepatitis C in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top